Selecta Biosciences Inc

NASDAQ:SELB  
3.11
+0.12 (+4.20%)
Other Pre-Announcement

Selecta Biosciences And Askbio Announce Updates To Methylmalonic Acidemia Program

Published: 04/29/2021 12:37 GMT
Selecta Biosciences Inc (SELB) - Selecta Biosciences and Askbio Announce Updates to Methylmalonic Acidemia (mma-101) Program.
Selecta Biosciences Inc - Selecta to Postpone Ind Submission Until at Least Q4 of 2021.
Selecta Biosciences Inc - Empty Capsid (sel-399) Study Remains on Track.
Selecta Biosciences Inc - Methylmalonic Acidemia (mma) Program to Become Wholly-owned by Selecta.
Selecta Biosciences Inc - Now Expects That Submission of Ind for Mma-101 and Immtor Will Be Delayed Until at Least Q4 of 2021.